A phase 1, multicenter, open-label, dose-escalation and expansion, safety, pharmacokinetic, pharmacodynamic, and clinical activity study of orally administered AG-881 in patients with advanced solid tumor, including gliomas, with an IDh1 and IDH2 mut
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Agios Pharmaceuticals, Inc.
Start Date
October 1, 2015
End Date
September 30, 2022
Administered By
Duke Cancer Institute
Awarded By
Agios Pharmaceuticals, Inc.
Start Date
October 1, 2015
End Date
September 30, 2022